EuroPCR 2023: Philips Revolutionizes Cardiology with Comprehensive Solutions for Patient Journey

Philips Omniwire

(IN BRIEF) Royal Philips is showcasing its end-to-end cardiology solutions at EuroPCR 2023 to deliver improved heart care with greater efficiency. The company’s comprehensive cardiology portfolio integrates imaging, devices, software, informatics, and services at every stage of the patient journey. Philips’ advanced physiology technologies enable interventionalists to perform ultra-low contrast percutaneous coronary intervention (ULC-PCI) procedures with enhanced confidence. Additionally, Philips’ clinical partners will present new data during late-breaking sessions, offering evidence-based insights to inform treatment decisions for patients undergoing percutaneous coronary intervention.

(PRESS RELEASE) AMSTERDAM,11-May-2023 — /EuropaWire/ —  Koninklijke Philips N.V. (NYSE: PHG, AMS: PHIA), a global leader in health technology, is set to showcase its end-to-end cardiology solutions at the annual meeting for the European Association of Percutaneous Cardiovascular Interventions (EuroPCR) in Paris, France, from May 16 to 19. With a focus on delivering improved heart care with enhanced efficiency, Philips aims to provide comprehensive solutions throughout the entire cardiac patient journey.

The Philips cardiology portfolio addresses the critical need for seamless integration of imaging, devices, software, informatics, and services at every stage of the care pathway. By offering advanced physiology technologies, Philips empowers interventionalists to perform ultra-low contrast percutaneous coronary intervention (ULC-PCI) procedures with heightened confidence and precision.

Furthermore, in line with its commitment to clinical excellence, Philips will present new data during late-breaking sessions at EuroPCR. These evidence-based findings, shared by Philips’ esteemed clinical partners, have the potential to significantly impact treatment decisions for patients undergoing percutaneous coronary intervention (PCI).

With its comprehensive cardiology solutions and commitment to clinical evidence, Philips continues to drive innovation and advance patient care in the field of cardiology.

  1. Dynamic Coronary Roadmap for Contrast Reduction Trial (DCR4Contrast): Prof. Javier Escaned, Head of the Interventional Cardiology Section at Hospital Clinico San Carlos in Madrid, Spain, will present the findings of the DCR4Contrast trial. This trial, the largest-ever randomized controlled clinical trial on the topic, investigated the effectiveness of Philips Dynamic Coronary Roadmap (DCR) in reducing the total volume of iodinated contrast media used during percutaneous coronary intervention (PCI) procedures, compared to PCI performed without DCR guidance. The late-breaker presentation is scheduled for Tuesday, May 16, from 12:00 to 13:30 CET in Room Maillot. Prof. Escaned will also be available to answer questions during the EuroPCR 2023 Press Conference on Tuesday, May 16, from 08:05 to 09:15 CET in the Press Room on Level 3.
  2. iFR versus FFR-Guided Revascularization Decision-Making: Dr. Takayuki Warisawa, an interventional cardiologist at NTT Medical Center in Tokyo, Japan, will present new data comparing the use of instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) in guiding revascularization decisions for left main ventricle disease. This late-breaker presentation adds to the growing body of evidence demonstrating how iFR can improve patient outcomes and optimize procedural results. The session is scheduled for Tuesday, May 16, from 12:00 to 13:00 CET in Room Maillot.
  3. DEFINE-FLAIR Five-Year Follow-Up: Prof. Javier Escaned will also present five-year data from the DEFINE FLAIR clinical trial, which compared patient outcomes using instant wave-free ratio (iFR) and fractional flow reserve (FFR) in the diagnosis and treatment of heart disease. This late-breaker presentation is scheduled for Thursday, May 18, from 15:15 to 16:45 CET in Room Maillot.
  4. Radiographic Imaging Validation and Evaluation for Angio iFR (ReVEAL iFR): Dr. Yoshinobu Onuma will present the results of the ReVEAL iFR study, a multi-center, prospective, single-arm, open-label data collection aimed at demonstrating the diagnostic performance of angiographic-derived iFR single-plane angiogram derived physiology model. This model uses invasive physiological measures of both iFR and FFR as reference standards. The late-breaker presentation will occur on Thursday, May 18, from 15:15 to 16:45 CET in Room Maillot.

For more information on these sessions and the complete EuroPCR 2023 program, please visit the following link.

At EuroPCR, Philips will highlight the latest innovations from its cardiology portfolio, including the Philips Image Guided Therapy System – Azurion, Philips Interventional Applications Platform – IntraSight, and visualization solutions such as Philips Precision Guidance System – SyncVision, Philips Dynamic Coronary Roadmap, EchoNavigator (a live echo and live X-ray fusion tool), OmniWire (Pressure Guide Wire), and IVUS catheters. In addition, Philips will showcase atherectomy solutions, including the AngioSculpt Evo RX PTCA Scoring Balloon Catheter and the ELCA coronary laser atherectomy catheter.

Physicians and media attendees can gain insights into the latest developments in optimizing ULC-PCI procedures through live expert-led training sessions, symposiums, and in-booth displays. Philips will also conduct IVUS Simulation Sessions, providing training on recognizing different types of calcified plaque using intravascular ultrasound (IVUS) and optical coherence tomography. Visitors to the Philips Training Village will have the opportunity to learn how Philips solutions support interventionalists in minimizing contrast load for patients and physicians, as well as in performing interventional procedures with clarity and confidence using technologies such as IVUS, iFR, FFR, and laser. These solutions aim to enhance the cardiac care experience for both staff and patients.

To access the full calendar of Philips events, register for sessions, and learn more about the cardiology solutions showcased at Philips Booth #F20 during EuroPCR 2023, please visit our website.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 74,000 employees with sales and services in more than 100 countries. News about Philips can be found at

Media contact:

Joost Maltha
Philips Global Press Office
Tel: +31 6 10 55 8116

SOURCE: Koninklijke Philips N.V.


Follow EuropaWire on Google News

Comments are closed.